

Digital Ulcers, Systemic Sclerosis Sine Scleroderma and Paraneoplastic Phenomena Responding to Bosentan Therapy

Itzhak Sharabi MD¹, Amir Tanay MD^{2,3} and Gisele Zandman-Goddard MD^{1,3}

¹Department of Medicine C, and ²Allergy, Immunology & Rheumatology Clinic, Wolfson Medical Center, Holon, Israel

³Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

KEY WORDS: digital ulcers, systemic sclerosis sine scleroderma, paraneoplastic disease, systemic sclerosis, bosentan

IMAJ 2015; 17: 126–127

Paraneoplastic syndrome is defined as a constellation of signs and symptoms that are secondary to the presence of a malignancy and can present as an atypical autoimmune disease. Regression of the rheumatologic disorder occurs following treatment of the underlying malignancy [1]. Systemic sclerosis (SSc) is a severe multi-organ disease characterized by widespread fibrosis and extensive vascular damage, and activation of the immune system with production of autoantibodies. The vascular involvement of SSc manifests as Raynaud's phenomenon (RP) and digital ulcers (DU) [2]. Most patients with SSc will develop limited or diffuse scleroderma while systemic sclerosis sine scleroderma is a rare variant of SSc [3]. We present the case of a patient with systemic sclerosis sine scleroderma who later developed lung cancer.

PATIENT DESCRIPTION

A 69 year old woman, a current smoker with a history of 80 pack-years, complained of pain and blue discoloration of the third digit of her right hand that began a few days earlier. Her past history included moderate chronic obstructive lung disease with 55% FEV1 on pulmonary function tests, malignant neoplasm of breast post-left

lumpectomy and radiotherapy in 2008, gastroesophageal reflux disease, hypertension and hyperlipidemia. She denied trauma to this hand, had not taken a new medication in the past 6 months, had not experienced thrombotic events in the past, and neither she nor her family had a history of Raynaud's phenomenon. There was no history of decreased appetite, weight loss, change in cough, or dyspnea. Her relevant medical therapy included aspirin, omepradex, cilazapril, simvastatin and tamoxifen.

The rheumatology examination revealed tenderness in the third digit of her right hand with transient blue discoloration, without evidence of calcinosis, thickening of the skin on the face, trunk or limbs, sclerodactyly, telangiectasis, or arthritis. Routine laboratory tests, including complete blood count, liver, renal and thyroid function, hypercoagulability tests, cardiolipin immunoglobulins (Ig) G and M antibodies and antinuclear antibodies (ANA), were all within normal limits. Ultrasound/Doppler of the right hand was normal. A computed tomography (CT) and CT angiography of the chest and abdomen and an echocardiogram were normal.

The patient was initially diagnosed with ischemia of the hand due to diffuse atherosclerosis. Despite treatment with enoxaparin and aspirin, the findings persisted. Over the next 2 months, her situation worsened further with cyanosis of all five digits of the right hand and in the fourth and fifth digits of the left hand accompanied by severe pain requiring therapy with opiates.

Treatment with iloprost 2 ng/kg/min IV over 6 hours was initiated for 3 weeks

together with high doses of oxycontin. Nevertheless, the patient eventually developed autoamputation of the distal phalanges of the third and fourth digits of her right hand.

Repeated serology for hypercoagulability, vasculitis and cancer markers were normal. However, a repeated serology in the same laboratory revealed elevated titers of ANA 1:320 and anticentromere antibodies that were initially negative during the first hospital admission. The patient was diagnosed with systemic sclerosis sine scleroderma where digital ulcers and the appropriate serological tests were the only manifestations of disease.

She was treated with bosentan 125 mg twice a day as a monotherapy and the response was immediate and dramatic. No new digital ulcers developed. Within 8 weeks, the necrotic areas disappeared and she could discontinue opiate therapy. The patient developed calcinosis of the finger beds.

One year after the initial presentation, she underwent a repeated CT chest scan for persistent cough which showed a 1 cm nodule in the left lower lobe and a 8 mm nodule in the left upper lobe. Fine-needle aspiration and pulmonary nodule biopsy from the two nodules revealed an adenocarcinoma on histology. Left video-assisted thoracoscopic surgery (VATS) wedge resection was performed to the nodule of the left lower lobe. Histology depicted adenocarcinoma, without vascular invasion (stage pT2A). In addition, stereotactic body radiotherapy (SBRT) to the nodule of the left upper lobe was performed. Follow-up

FDG-PET-CT (fluorodeoxyglucose-positron emission tomography-CT) revealed no pathological activity in either nodule, indicating complete remission. During the entire period the patient continued therapy with bosentan. No recurrence of digital ulcer occurred over 2 years of follow-up.

COMMENT

This is an unusual presentation of SSc sine scleroderma where the hallmark single feature was severe digital necrotic ulcers. The patient did not develop thickened skin, Raynaud’s phenomenon or visceral disease, and the diagnosis was based on the single manifestation and appropriate autoantibody status which included elevated titers of ANA and anticentromere antibodies. Hence, we could not classify the patient as limited or diffuse scleroderma [4]. The unusual manifestation of SSc sine scleroderma was actually the expression of an occult cancer that became clinically evident within a year. In one study, SSc sine scleroderma was found in 8.3% of 947 patients in a SSc cohort. The diagnosis was determined in patients who suffered from Raynaud’s phenomenon, positive ANA, and one visceral involvement. These patients were more often females, had anticentromere antibodies, and 12.5% were referred from vascular surgery due to digital ulcers. Digital ulcers were present in 24.1% of these patients. These findings correlate with our case [3]. The unusual findings prompted us to search for paraneoplastic disease. The literature lacks information regarding the systemic sclerosis sine scleroderma subset and the association with paraneoplastic syndrome.

We reviewed the literature and identified another 14 reported cases of digital ulcer as a paraneoplastic syndrome of lung cancer [Table 1]. The male to female ratio was 1.8:1, and the age range was 40–78 years in males and 52–69 years in females. Eighty percent of the patients developed digital ischemia/ulcer or Raynaud’s syndrome within a year prior to diagnosis of lung carcinoma; 33%, including our patient, had elevated titers of ANA, and only 13%

Table 1. Paraneoplastic digital ulcers and/or paraneoplastic Raynaud’s syndrome in lung carcinoma

No.	Author, year	Age/Gender	Serologic investigation	Histological type of lung cancer
1	Sharabi et al. (present)	69/ F	ANA positive 1:320, anticentromere positive, anticardiolipin negative	Adenocarcinoma
2	Adedayo, 2012	40/ M	ANA, antiphospholipid antibody, anticardiolipin, lupus anticoagulant – all negative	Non-small cell
3	Moulakakis, 2010	70/ M	N/A	Lung Ca diagnosed by CT only
4	Schildmann, 2010	78/ M	ANA negative	Non-small cell
5	Schmid, 2008	62/ F	ANA, RF, cryoglobulin, ANCA, HIV – all negative	Non-small cell
6	Kopterides, 2004	65/ F	ANA, antiphospholipid anticardiolipin, RF and cryoglobulin – all negative	Adenocarcinoma
7	Wong, 2003	62/ M	ANA, RF, extractable nuclear negative	Non-small cell
8	Imandi, 2002	73/ M	ANA positive 1:1280	Small cell
9	Vaidya, 2001	52/ F	ANA positive 1:320 elevated IgG anticardiolipin	Non-small cell
10	Wang, 1996		Elevated cryoglobulinemia	Non-small cell
11	Arrowsmith, 1991	63/ M	Positive Hep2 cell substrate for centromere-specific ANA 1:2560	Small cell
12	Wilmalaranta, 1987	69/ M	ANA, RF, cryoglobulin – all normal	Adenocarcinoma
13	Field, 1986	70/ M	ANA, RF cryoglobulin – all negative	Small cell anaplastic carcinoma
14	Petri, 1985	62/ M	ANA positive 1:320	Adenocarcinoma
15	Domz, 1961	50/ F	Elevated cryoglobulinemia	Adenocarcinoma

ANA = antinuclear antibody, N/A = not available, RF = rheumatoid factor, ANCA = antineutrophil cytoplasmic antibodies, HIV = human immunodeficiency virus

had elevated anticentromere antibody titers. Of the 15 reported cases, 5 had adenocarcinoma.

Bosentan, an endothel-1 antagonist, is beneficial for digital ulcers in SSc [5]. Compared to the 14 other cases of paraneoplastic digital ischemia/ulcer that we reviewed, our case was the only one, to our knowledge, where bosentan was initiated and proved effective as treatment for paraneoplastic digital ulcer, showed an excellent response on healing, and prevented new ulcers despite ongoing cancer.

In conclusion, this case emphasizes that patients who develop unusual manifestations of systemic sclerosis, like SSc sine scleroderma with digital ischemia and digital ulcer in whom the accepted causes have been excluded, deserve the fullest investigation in an attempt to discover an occult malignancy. We emphasize that the digital ulcers responded immediately to therapy with bosentan, before the malignancy was removed.

Correspondence

Dr. G. Zandman-Goddard

Dept. of Medicine C, Wolfson Medical Center, Holon 58100, Israel

Phone: (972-3) 502-8674

Fax: (972-3) 502-8810

email: goddard@wolfson.health.gov.il

References

1. Racanelli V, Prete M, Minoia C, Favino E, Perosa F. Rheumatic disorders as paraneoplastic syndromes. *Autoimmunity Rev* 2008; 7: 352-8.
2. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. *N Engl J Med* 2009; 360: 1989-2003.
3. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. *Arthritis Rheum* 2013; 65: 2737-47.
4. Marangoni RG, Rocha LF, Del Rio APT, et al. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. *Rheumatology* 2013; 52: 1520-4.
5. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis* 2011; 70: 32-8.